![](/img/cover-not-exists.png)
PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK—A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
AG Olsson, MM Jensen, SK Gandhi, KM Fox, T PaulssonVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72433-0
File:
PDF, 77 KB
english, 2010